Higher densities of CD3+ (p = 0.01), CD8+ (p = 0.006), and PD-1+ (p = 0.024) tumor-associated T cells were associated with higher T category (≥T3a per the 7th edition of the American Joint Committee on Cancer staging manual). Higher tumor cell expression of PD-L1 ...
We monitored expression of PD-1 (a mediator of T-cell exhaustion and viral persistence) on hepatitis C virus (HCV)-specific CD8(+) and CD4(+) T cells from blood and liver during acute and chronic infections and after the resolved infection stage. PD-1 expression on HCV-specific T cells...
The FDA has approved cemiplimab-rwlc (Libtayo) monotherapy for use in the frontline treatment of patients with advanced non–small cell lung cancer (NSCLC) with a PD-L1 expression level of 50% or higher.1 The decision was based on data from an analysis of 710 patients with a PD-L1 e...
Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia 喜欢 0 阅读量: 47 作者: Yang,W.,Song,Y.,Lu,Y.-L.,Sun,J.-Z.,Wang,H.-W....
Pembrolizumab appears promising for patients with programmed cell death ligand-1 (PD-L1)-positive solid tumors. However, data on immunotherapy for biliary tract cancers (BTC) are limited. We aimed to investigate the predictive value of PD-L1 expression as an immunotherapeutic biomarker in BTC. Pati...
与治疗前BCC样本相比,抗PD-1治疗后,Mac_s2细胞中TREM2hi巨噬细胞marker整体水平下调,而B_sc2中B_c22B细胞marker整体水平显著上调。这些发现表明,在免疫治疗反应的背景下,黑色素瘤和基底细胞癌中的特征性基因表达发生类似的改变。 Supplementary Figure 9 ...
the molecular mechanisms that may be responsible for the poor prognosis of these tumors, revealed that FGF-2 expression correlates positively with the expression of epithelial to mesenchymal transition (EMT)-promoting transcription factors and with changes in gene expression that are characteristic of ...
PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis Programmed cell death-ligand 1 (PD-L1) has emerged as a potential biomarker for selection of patients more likely to respond to ...
We examined the expression of Programmed Death Ligand 1 (PD-L1) and defined the tumor immune microenvironment ... P Koirala,ME Roth,J Gill,... - 《Sci Rep》 被引量: 30发表: 2016年 Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-...
As PD-L1 expression is a continuous biomarker that correlates with immunotherapy efficacy in NSCLC [1., 2., 3.], we hypothesized that among patients with NSCLC and a PD-L1 expression level of 50%–100%, those with the highest levels of PD-L1 expression would experience improved clinical ou...